Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 13/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | HTR7 | P34969 | 5/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | DRD4 | P21917 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13789662 | 0.91 | HIF1A (0.61) | HIF1AALDH1A1LMNAPKMTSHR | |
| SCHEMBL1593598 | 0.90 | HIF1A (0.92) | HIF1AALDH1A1LMNAPKMTSHR | |
| SCHEMBL4508960 | 0.86 | HIF1A (0.81) | HIF1AALDH1A1LMNAPKMTSHR | |
| SCHEMBL12610265 | 0.86 | HIF1A (1.00) | HIF1AALDH1A1LMNAPKMTSHR | |
| SCHEMBL1593340 | 0.86 | HIF1A (0.75) | HIF1AALDH1A1LMNAPKMTSHR | |
| SCHEMBL1593540 | 0.85 | HIF1A (0.74) | HIF1AALDH1A1LMNAPKMTSHR | |
| SCHEMBL4527044 | 0.84 | HIF1A (0.72) | HIF1AALDH1A1LMNAPKMTSHR | |
| SCHEMBL1593685 | 0.83 | HIF1A (0.70) | HIF1AALDH1A1LMNAPKMTSHR | |
| SCHEMBL14473822 | 0.80 | HIF1A (0.57) | HIF1AALDH1A1LMNAPKMTSHR | |
| SCHEMBL1593047 | 0.80 | HIF1A (0.65) | HIF1AALDH1A1LMNAPKMTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090170834-A1 | Fused Pyrimidones and Thiopyrimidones, and Uses Thereof | PROLEXYS PHARMACEUTICALS, INC. (US) | 2009-07-02 | — | — | US | disclosed |
| US-20090170834-A1 | Fused Pyrimidones and Thiopyrimidones, and Uses Thereof | PROLEXYS PHARMACEUTICALS, INC. (US) | 2009-07-02 | — | — | US | disclosed |
| US-20090170834-A1 | Fused Pyrimidones and Thiopyrimidones, and Uses Thereof | PROLEXYS PHARMACEUTICALS, INC. (US) | 2009-07-02 | — | — | US | disclosed |
| WO-2007076085-A2 | FUSED PYRIMIDONES AND THIOPYRIMIDONES, AND USES THEREOF | PROLEXYS PHARMACEUTICALS, INC . (US) | 2007-07-05 | — | — | WO | disclosed |
| WO-2007076085-A2 | FUSED PYRIMIDONES AND THIOPYRIMIDONES, AND USES THEREOF | PROLEXYS PHARMACEUTICALS, INC . (US) | 2007-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170834-A1 | Fused Pyrimidones and Thiopyrimidones, and Uses Thereof | TYMP, TYMS, MKI67 | HIF1A 3569/4885ALDH1A1 596/4885LMNA 4361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.